Compare CGEM & HIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGEM | HIPO |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | 540 |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.7M | 737.1M |
| IPO Year | 2020 | N/A |
| Metric | CGEM | HIPO |
|---|---|---|
| Price | $15.16 | $24.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | $30.13 | ★ $38.67 |
| AVG Volume (30 Days) | ★ 998.3K | 101.7K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | $5.20 | $22.33 |
| P/E Ratio | ★ N/A | $7.64 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.68 | $24.08 |
| 52 Week High | $16.74 | $38.98 |
| Indicator | CGEM | HIPO |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 31.90 |
| Support Level | $11.92 | N/A |
| Resistance Level | $16.21 | $26.93 |
| Average True Range (ATR) | 0.96 | 0.86 |
| MACD | 0.03 | -0.16 |
| Stochastic Oscillator | 56.07 | 1.35 |
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.